U.S. Food & Drug Administration: 10903 New Hampshire Avenue Silver Spring, MD 20993
U.S. Food & Drug Administration: 10903 New Hampshire Avenue Silver Spring, MD 20993
Re: K201796
Trade/Device Name: 1717SCV, 1717SGV
Regulation Number: 21 CFR 892.1680
Regulation Name: Stationary x-ray system
Regulatory Class: Class II
Product Code: MQB
Dated: June 19, 2020
Received: June 30, 2020
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced
above and have determined the device is substantially equivalent (for the indications for use stated in the
enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the
enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance
with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a
premarket approval application (PMA). You may, therefore, market the device, subject to the general
controls provisions of the Act. Although this letter refers to your product as a device, please be aware that
some cleared products may instead be combination products. The 510(k) Premarket Notification Database
located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination
product submissions. The general controls provisions of the Act include requirements for annual registration,
listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We
remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be
subject to additional controls. Existing major regulations affecting your device can be found in the Code of
Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements
concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA
has made a determination that your device complies with other requirements of the Act or any Federal
statutes and regulations administered by other Federal agencies. You must comply with all the Act's
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see
https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-
combination-products); good manufacturing practice requirements as set forth in the quality systems (QS)
regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for
combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-
542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part
807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part
803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-
mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including
information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the
Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See
the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE
by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For
Thalia T. Mills, Ph.D.
Director
Division of Radiological Health
OHT7: Office of In Vitro Diagnostics
and Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
510(k) Submission – 1717SCV / 1717SGV K201796
This summary of 510(k) safety and effectiveness information is being submitted in accordance with
requirements of 21 CFR Part 807.92.
Name of the device, including the trade or proprietary name if applicable, the common or usual name
and the classification name, if known:
2. Device Description
1717SCV / 1717SGV is a digital solid state X-ray detector that is based on flat-panel technology. This
radiographic image detector and processing unit consists of a scintillator coupled to an a-Si TFT sensor.
This device needs to be integrated with a radiographic imaging system. It can be utilized to capture and
digitalize X-ray images for radiographic diagnosis.
1717SCV and 1717SGV have the same Hardware, Software and components.
The type of scintillator layer are different: Cesium Iodide for 1717SCV and Gadolinium Oxsulfide for
1717SGV. Scintillator is a phosphor that produces scintillations.
The subject detectors are not wireless, but they are connected to a viewing station by ethernet
connection. Also, the subject detectors have an Automatic Exposure Control (AEC) feature.
The RAW files can be further processed as DICOM compatible image files by separate console SW
(K190866 / Xmaruview V1 (Xmaru Chiroview, Xmaru Podview)/ Rayence Co.,Ltd.) for a radiographic
diagnosis and analysis.
The software used with the subject detectors is the same as the software XmaruView V1 used with the
predicate K190866.
2
510(k) Submission – 1717SCV / 1717SGV K201796
3
510(k) Submission – 1717SCV / 1717SGV K201796
Feature
Feature
1717SCV and 1717SGV digital flat panel X-ray detectors in comparison with 1717SCC and 1717SGC have
the same indications for use, the same imaging area (17 x 17), based on the same scintillator material (CsI:Tl
for SCV and SCC, Gd2O2S:Tb for SGV and SGC ), same resolution performance. The pixel matrix for
each pixel pitch size (127 um and 140 um) for both the subject devices and the predicate devices are
identical. The recommended generator specifications for both the subject device and the predicate device
remains the same.
The non-clinical test report for each subject device was prepared and submitted to FDA separately to
demonstrate the substantial equivalency of the subject devices compared to each respective predicate device.
The non-clinical test report contains the MTF, DQE and NPS test results of 1717SCV and 1717SGV by
using the identical test equipment and same analysis method described by IEC 62220-1.
The MTF and DQE represent the ability to visualize object details of a certain size and contrast. 1717SCV
and 1717SGV have similar MTF and DQE performance in comparison with 1717 SCC and 1717SGC,
respectively, at all spatial frequencies.
The power adapter for 1717SCV and 1717SGV has been updated to RP005A from RS1717.
The electrical safety test data demonstrates that the new power adapter is safe and effective.
6
510(k) Submission – 1717SCV / 1717SGV K201796
8. Conclusions:
Based on the non-clinical consideration for both devices, Rayence, the sponsor, claims the substantial
equivalency between the subject devices and their predicate devices in terms of diagnostic image quality
without new concern for safety and effectiveness.